Screen for CRC with a proven blood test.

  • Highly Accurate
    Validated by the ECLIPSE study, published in the NEJM1
  • 90% Adherence
    Shown in real-world settings2*
  • Expanding Coverage
    For eligible patients with Medicare, VA Community Care, and TRICARE
  • Highly Accurate
    ECLIPSE study, published in the NEJM1
  • 90% Adherence
    Shown in real-world settings2*
  • Expanding Coverage
    Medicare, VA Community Care, and TRICARE

*For eligible patients

“I've had a lot of success getting patients to screen with Shield.”

— Yulia Koltzova-Rang, MD

Internal Medicine

*Dr. Yulia Koltzova-Rang is a paid consultant of Guardant Health.

*Dr. Yulia Koltzova-Rang is a paid consultant of Guardant Health.

Simplify CRC screening
with the Shield™ blood test

  • Create the
    Order

    a Shield order

  • +

  • Collect Blood
    Sample

    the patient’s
    blood sample

  • =

  • Complete

    by shipping the sample, and receive results within ~2 weeks

Get set up to offer Shield

Do you have a patient in mind for Shield?

Do you offer in-office phlebotomy?

Not sure how to answer?

Answer "Yes" if you have:

  • No prior diagnosis of colorectal cancer, adenomatous polyps, or inflammatory bowel disease
  • No personal diagnosis or family history of colorectal cancer or known genetic disorders such as Lynch syndrome or familial adenomatous polyposis

Are you affiliated with a health system?

Not sure how to answer?

Answer “No,” if you’ve completed any of the following screening tests:

  • Colonoscopy within the last 10 years

Or either of the following stool tests:

  • FIT/FOBT — in the last year
  • FIT-DNA — in the last 1-3 years
Next

Important Product Information

Intended Use

The Shield™ test is a qualitative, in vitro diagnostic test intended to detect colorectal cancer derived alterations in cell-free DNA from blood collected in the Guardant Shield Blood Collection Kit.
Shield is intended for colorectal cancer screening in individuals at average risk for the disease, age 45 years or older. Patients with a positive result should be followed by colonoscopy. Shield is not a replacement for diagnostic colonoscopy or for surveillance colonoscopy in high-risk individuals. This test is performed at Guardant Health, Inc.

Precaution: Based on data from clinical studies, Shield has limited detection (55%-65%) of Stage I colorectal cancer and does not detect 87% of precancerous lesions. One out of 10 patients with a negative Shield result may have a precancer that would have been detected by a screening colonoscopy. Shield demonstrated high detection of Stages II, III, and IV colorectal cancer.

Limitations and Other Important Information: The Shield test is not intended for patients that have personal history of colorectal cancer, adenomas, or other related cancers; or those who had a positive result on another colorectal cancer screening method within the last six months, have been diagnosed with a condition associated with high risk for colorectal cancer such as Inflammatory Bowel Disease (IBD), chronic ulcerative colitis (CUC), Crohn’s disease; or who have a family history of colorectal cancer, or certain hereditary syndromes. Providers should discuss the most appropriate screening test to use with patients depending on their medical history and individual circumstances. Shield may produce a false negative or false positive result. A false negative result may occur when the Shield test does not detect a colorectal tumor signal while a colonoscopy identifies a colorectal cancer. A negative result does not guarantee the absence of colorectal cancer or advanced adenoma, and patients should continue participating in colorectal cancer screening programs at the appropriate guideline-recommended intervals. A false positive result may occur when the Shield test generates a positive result while a colonoscopy will not find colorectal cancer or advanced adenoma.

Please read our Patient Fact Sheet for complete product information about the Shield test including full safety information.

Shield is available by Rx only.

*Medicare Advantage patients may be subject to co-pays, co-insurances, and deductibles, depending on their specific plan.

  1. References:
  2. Chung DC et al., NEJM, 2024 — the ECLIPSE study cited wherever test performance is shown.
  3. Data on file. Guardant Health, Inc. Internal data on file, various collection dates (e.g., November 2024, March 2024, June 2022, January 2025) depending on context in each figure or claim.